Abstract:
Objectives: To assess the processes and clinical outcomes of a joint collaboration between Antimicrobial Stewardship Program (ASP) and the Outpatient Parenteral Antimicrobial Therapy (OPAT) unit for delivery of monoclonal antibody therapy for mild-to-moderate COVID-19.
Methods: We carried out a retrospective, interim analysis of our COVID-19 monoclonal antibody therapy program. Outcomes included clinical response, incidence of hospitalization, and adverse events.
Results: 175 patients (casirivimab-imdevimab, n=130; bamlanivimab, n=45) were treated between Dec 2020 and Mar 1, 2021. The median time from symptom onset was 6 (IQR 4,8) days at time of treatment. Of 135 patients available for follow up, 71.9% and 85.9% of patients reported symptom improvement within 3 and 7 days of treatment, respectively. Nine (6.7%) patients required a COVID-19 related hospitalization within 14 days of treatment for progression of symptoms. Seven (4%) patients experienced an infusion-related reaction.
Conclusions: An ASP-OPAT collaboration is a novel approach to implement an efficient and safe monoclonal antibody therapy program for the treatment of mild-to-moderate COVID-19.
Reference:Rodriguez GD, Wu Y, Karnik K, Ruddy S, Kula A, Warren N, Yashayev R, Sajid F, Prasad N, Yoon J, Turett G, Yung L, Urban C, Lee CH, Abraham J, Cooke JT, Sharma M, Jaffer A, Segal-Maurer S. Implementation of a Collaborated Antimicrobial Stewardship Program and Outpatient Parenteral Antimicrobial Therapy (OPAT) Unit-driven Monoclonal Antibody Therapy Program for COVID-19 at a NYC Hospital. Int J Infect Dis. 2022 Mar 3:S1201-9712(22)00137-0. doi: 10.1016/j.ijid.2022.02.056. Epub ahead of print. PMID: 35248718; PMCID: PMC8893929.